Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Conditions
- Invasive Breast Cancer
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 650
- Registration Number
- NCT03595592
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital Virgen de la Nieves, Granada, Spain
🇮🇹Ospedale Santa Maria della Misericordia, Udine, Italy
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Cancer of Unknown Primary Site
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: CarboplatinDrug: IpatasertibDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Conditions
- Central Nervous System MetastasesHER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 19
- Registration Number
- NCT03417544
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Conditions
- HER2-negative Breast Cancer
- Interventions
- Drug: DoxorubicinDrug: CyclophosphamideDrug: Weekly PaclitaxelDrug: TrastuzumabDrug: PertuzumabDiagnostic Test: Celcuity CELx HSF
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 64
- Registration Number
- NCT03412643
- Locations
- 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- Conditions
- Locally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT03329378
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Mount Sinai West, New York, New York, United States
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Conditions
- Breast NeoplasmsBreast Diseases
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT03304080
- Locations
- 🇺🇸
Perlmutter Cancer Center NYU Langone, New York, New York, United States
🇺🇸New York Presbyterian Weill Cornell Medical Center, New York, New York, United States
🇺🇸New York Presbyterian Columbia Irving Comprehensive Cancer Center, New York, New York, United States
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 480
- Registration Number
- NCT03264547
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- Conditions
- Unresectable HER2-Positive Breast CarcinomaStage III Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Metastatic Breast AdenocarcinomaMetastatic HER2-Positive Breast CarcinomaRecurrent Breast AdenocarcinomaRecurrent HER2-Positive Breast CarcinomaUnresectable Breast Carcinoma
- Interventions
- Drug: AtezolizumabProcedure: BiopsyProcedure: Bone ScanProcedure: Computed TomographyDrug: DocetaxelProcedure: Magnetic Resonance ImagingDrug: PaclitaxelOther: Placebo AdministrationBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: Trastuzumab
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 190
- Registration Number
- NCT03199885
- Locations
- 🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03135171
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Yale University, New Haven, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03125928
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.